Document Detail


Is etoricoxib effective in preventing heterotopic ossification after primary total hip arthroplasty?
MedLine Citation:
PMID:  23359100     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: Heterotopic ossification is a common complication after total hip arthroplasty. Non-steroidal anti-inflammatory drugs (NSAIDs) are known to prevent heterotopic ossifications effectively, however gastrointestinal complaints are reported frequently. In this study, we investigated whether etoricoxib, a selective cyclo-oxygenase-2 (COX-2) inhibitor that produces fewer gastrointestinal side effects, is an effective alternative for the prevention of heterotopic ossification.
METHODS: We investigated the effectiveness of oral etoricoxib 90 mg for seven days in a prospective two-stage study design for phase-2 clinical trials in a small sample of patients (n = 42). A cemented primary total hip arthroplasty was implanted for osteoarthritis. Six months after surgery, heterotopic ossification was determined on anteroposterior pelvic radiographs using the Brooker classification.
RESULTS: No heterotopic ossification was found in 62 % of the patients that took etoricoxib; 31 % of the patients had Brooker grade 1 and 7 % Brooker grade 2 ossification.
CONCLUSIONS: Etoricoxib seems effective in preventing heterotopic ossification after total hip arthroplasty. This finding further supports the use of COX-2 inhibitors for the prevention of heterotopic ossification following total hip arthroplasty.
Authors:
Jaap J Brunnekreef; Paul Hoogervorst; Marieke J Ploegmakers; Wim H Rijnen; Berend W Schreurs
Publication Detail:
Type:  Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't     Date:  2013-01-29
Journal Detail:
Title:  International orthopaedics     Volume:  37     ISSN:  1432-5195     ISO Abbreviation:  Int Orthop     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-03-28     Completed Date:  2013-10-18     Revised Date:  2014-04-01    
Medline Journal Info:
Nlm Unique ID:  7705431     Medline TA:  Int Orthop     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  583-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Aged
Aged, 80 and over
Arthroplasty, Replacement, Hip / adverse effects*
Cyclooxygenase 2 Inhibitors / administration & dosage,  adverse effects,  therapeutic use*
Dose-Response Relationship, Drug
Female
Hip Joint / radiography,  surgery
Hip Prosthesis
Humans
Male
Middle Aged
Ossification, Heterotopic / etiology*,  prevention & control*
Osteoarthritis, Hip / surgery*
Prospective Studies
Pyridines / administration & dosage,  adverse effects,  therapeutic use*
Severity of Illness Index
Sulfones / administration & dosage,  adverse effects,  therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Cyclooxygenase 2 Inhibitors; 0/Pyridines; 0/Sulfones; 202409-33-4/etoricoxib
Comments/Corrections
Comment In:
Int Orthop. 2013 Aug;37(8):1629   [PMID:  23736968 ]
Int Orthop. 2013 Aug;37(8):1631   [PMID:  23778642 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Biomechanical testing of a new plate system for the distal humerus compared to two well-established ...
Next Document:  From the mouths of babes: Dental caries in infants and children and the intensification of agricultu...